Niche CRO Invivotek specializes in small animal in vivo preclinical studies for drug discovery and early optimization, presenting opportunities to offer targeted preclinical collaborations, extensions in immunology, oncology, metabolic, and cardiovascular programs, and potential upsell of biomarker and mechanism of action studies.

Global Experience With a global preclinical focus and a history of projects since 2013, there is potential to pitch expanded geographic support, multi-site study designs, and scalable services to biotech companies pursuing international regulatory pathways.

Midmarket Fit Revenue in the 1–10M range and a smaller team (11–50 employees) indicate a match for mid-market biotech firms seeking agile, cost-efficient preclinical CRO partnerships with flexible engagement models.

Full-Funnel Capabilities Invivotek combines in vivo testing with biochemical, molecular biology, and primary cell assays, enabling comprehensive study portfolios that can be pitched as end-to-end preclinical solutions, including mechanism of action and biomarker discovery support.

Growth Signals Recent press and ongoing tech stack investments (website, analytics, and digital presence) suggest an openness to partner in marketing, data-driven collaboration, and enhanced communications to prospective clients in Immunology, Oncology, and related therapeutic areas.